Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Stuttgart
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Orexigen Therapeutics Inc

+ Add to Watchlist

JXS:GR

6.043 EUR 0.234 4.03%

As of 02:16:02 ET on 05/04/2015.

Snapshot for Orexigen Therapeutics Inc (JXS)

Open: 5.840 Day's Range: 5.837 - 6.043 Volume: 0
Previous Close: 5.809 52wk Range: 2.226 - 8.013 1-Yr Rtn: +48.99%

Stock Chart for JXS

No chart data available.
  • JXS:GR 6.043
  • 1D
  • 1M
  • 1Y
5.809
Interactive JXS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for JXS

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.5420
Est. PEG Ratio -
Market Cap (M EUR) 754.86
Shares Outstanding (M) 124.91
30 Day Average Volume 217
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for JXS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for JXS

Orexigen Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system (CNS) disorders with an initial focus on obesity.

Michael Narachi "Mike"President/CEOJoseph P Hagan "Jay"Acting CFO/Chief Bus Officer
Tom CannellChief Commercial OfficerHeather D TurnerSenior VP/Secretary/Gen Cnsl
More Company Profile & Key Executives for JXS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil